Understanding the causes of Rhabdomyosarcoma and its aggressive behavior
Oncogenic Drivers of Rhabdomyosarcoma Cell State, Cancer Stem Cells and Metastasis
This study is looking at a tough type of cancer called fusion-negative rhabdomyosarcoma to find out how certain cancer cells keep growing and spreading even when treated, with the goal of creating better treatments to help patients live longer and healthier lives.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11078783 on NIH RePORTER |
What this research studies
This research focuses on Rhabdomyosarcoma (RMS), particularly the fusion-negative subtype, which is known for its aggressive nature and poor survival rates. The team aims to identify cancer stem cells (CSCs) and the molecular pathways that allow these cells to grow and spread despite treatment. By understanding these mechanisms, the researchers hope to develop new therapies that can effectively target and eliminate these resistant cancer cells, potentially leading to better outcomes for patients. The study employs advanced techniques to analyze the genetic and molecular characteristics of these cancer cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with fusion-negative Rhabdomyosarcoma, particularly those who have experienced treatment resistance or metastasis.
Not a fit: Patients with other types of cancers or those who do not have Rhabdomyosarcoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for Rhabdomyosarcoma, improving survival rates for affected patients.
How similar studies have performed: Other research has shown promise in targeting cancer stem cells in various cancers, suggesting that this approach could be effective for Rhabdomyosarcoma as well.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Langenau, David Michael — Massachusetts General Hospital
- Study coordinator: Langenau, David Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.